Key result
Narrative review summarizes clinical evidence on low-dose colchicine and inflammation in CVD.
Why the study?
Although colchicine shows promise in secondary prevention after myocardial infarction, its efficacy remains somewhat controversial across randomized trials such as CLEAR SYNERGY.
Does low-dose colchicine improve cardiovascular outcomes in patients with post-myocardial infarction and stable chronic coronary syndrome?
Review Narrative
Does low-dose colchicine improve cardiovascular outcomes in patients with post-myocardial infarction and stable chronic coronary syndrome?
Low-dose colchicine provides long-term cardiovascular benefits in stable chronic coronary syndrome, though its efficacy in acute post-MI patients requires further optimization.
Answers are grounded in this paper and cite their sources.
Supports low-dose colchicine in stable CCS with post-MI caution; leaves open acute optimization pending dedicated trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Karpuz et al. (2026) reported a review narrative. This is a narrative review article summarizing clinical evidence on inflammation, cardiovascular diseases, and colchicine, without primary clinical trial data or quantitative results.
Synapse has enriched 10 related papers. Consider them for comparative context: